The approval of Tyruko by European authorities is a significant milestone for Novartis' Sandoz division. This could potentially increase Novartis' market share in the European healthcare sector, as Tyruko is the first and only biosimilar for multiple sclerosis in Europe. This news is highly relevant and important for NVS investors, as it could positively impact the company's revenues and profitability in the short term.